Alnylam Pharmaceuticals (ALNY) Income from Continuing Operations (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Income from Continuing Operations came in at 164494000.0 in Q2 2026, up 327.74% YoY from 38456295.94 in Q2 2025, and down 20.15% on a QoQ basis from 205991000.0 in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Income from Continuing Operations data on file, last reported at 164494000.0 in Q2 2026.
- Quarterly Income from Continuing Operations rose 327.74% year-over-year to 164494000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 774711000.0 (up 371.06% YoY) and the FY2025 annual result came in at 313747000.0, up 212.79% from the prior year.
- Income from Continuing Operations declined to 164494000.0 in Q2 2026, from 205991000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 292683000.0 in Q3 2025 to a low of 405920000.0 in Q3 2022.
- A 5-year average of 64740166.67 and a median of 77995500.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations sank 327.66% — and 2026, when it soared 1228.66%.
- Tracing ALNY's Income from Continuing Operations over 5 years: stood at 207493000.0 in 2022, then soared by 33.55% to 137870000.0 in 2023, then soared by 39.24% to 83763000.0 in 2024, then jumped by 233.17% to 111543000.0 in 2025, then surged by 47.47% to 164494000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 164494000.0 (Q2 2026), 205991000.0 (Q1 2026), and 111543000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 164.49 Mn |
| Mar 31, 2026 | 205.99 Mn |
| Dec 31, 2025 | 111.55 Mn |
| Sep 30, 2025 | 292.68 Mn |
| Jun 30, 2025 | -66.28 Mn |
| Mar 31, 2025 | -18.25 Mn |
| Dec 31, 2024 | -83.76 Mn |
| Sep 30, 2024 | -111.57 Mn |
| Jun 30, 2024 | -16.89 Mn |
| Mar 31, 2024 | -65.94 Mn |
| Dec 31, 2023 | -137.87 Mn |
| Sep 30, 2023 | 147.75 Mn |
| Jun 30, 2023 | -276.02 Mn |
| Mar 31, 2023 | -174.10 Mn |
| Dec 31, 2022 | -207.49 Mn |
| Sep 30, 2022 | -405.92 Mn |
| Jun 30, 2022 | -277.40 Mn |
| Mar 31, 2022 | -240.34 Mn |
| Dec 31, 2021 | -258.46 Mn |
| Sep 30, 2021 | -204.51 Mn |